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Pfizer's Viagra Patent and the Promise of
Patent Protection in China
JEFFREY A. ANDREWS*
I. INTRODUCTION
On July 7, 2004, Pfizer Inc. announced that the Chinese State
Intellectual Property Organization (SIPO) Patent Reexamination
Board had overturned Pfizer's patent for sildenafil citrate, the
main ingredient in the popular erectile dysfunction drug Viagra.1
The response from Pfizer and from other international or
multinational pharmaceutical companies was immediate.2 Legal
and business commentators postulated that China was
demonstrating its inability to conduct itself in accordance with the
guidelines set by its membership in the World Trade Organization
(WTO) and was regressing back to its old ways of state-tolerated
violations of intellectual property rights Approximately one
* Associate, Locke Liddell & Sapp LLP, Houston, Texas; J.D., University of Houston Law
Center; Ph.D., Duke University; M.F.S., Yale University; B.S., B.A., University of
Rochester. The author is grateful to Prof. Chenglin Liu for his outstanding teaching of
Chinese law.
1. Associated Press, Chinese Dismiss Patent for Viagra, SAN JOSE MERCURY NEWS,
July 7, 2004, available at 2004 WLNR 2937426.
2. Associated Press, Pfizer Patent for Viagra Overturned in China, CHI. SUN TIMES,
July 8, 2004, available at 2004 WLNR 11709102 (quoting Pfizer Inc.'s statement that "[the
company] is extremely disheartened by this recent action" and noting that foreign drug
companies had been watching the Pfizer case as a test of China's commitment to
intellectual property rights); Jake Lloyd-Smith, U.S. Drug Giant Lashes Out at China
Patent Decision, May Curb Investment, CAN. PRESS, July 16, 2004, available at 2004
WLNR 85647918 ("Pfizer Inc.... lashed out Friday at Chinese regulators' recent decision
to overturn its local patent for Viagra, warning that it might cut future investment in the
world's most populous country.").
3. See, e.g., China's Viagra Heist, ASIAN WALL ST. J., July 9, 2004, at A7 ("[Tihis
week China decided to ignore market principles, its own World Trade Organization
commitments and the long-term interests of its people by overturning [Pfizer's sildenafil
citrate] patent"); James B. Altman, Greg Mastel, & Daniel P. Wendt, Smart Pills:
Protecting IP Rights Overseas, IP LAW & BUSINESS, Sept. 2004, at 22; Phelim Kyne, Pfizer
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month after the China SIPO announcement regarding the Pfizer
patent, U.K. pharmaceuticals company GlaxoSmithKline PLC
abandoned its formulation patent for rosiglitazone, the major
component of its diabetes drug Avandia, in the face of a patent
challenge by three Chinese drug makers. Glaxo cited the China
SIPO decision regarding the Viagra patent as indicating that Glaxo
would be unable to obtain meaningful protection of this important
drug.'
Fallout from the Pfizer patent case continues, and the long-
term significance of the China SIPO decision remains uncertain. 6
However, despite the complaints of Pfizer and the pharmaceutical
industry, the Pfizer case clearly indicates the continuing
development and progress of the Chinese patent law system. As
noted recently by Professor Peter Yu, the action taken by the
Chinese pharmaceutical industry to legally challenge the Pfizer
patent demonstrates significant progress by China toward rule of
law in the intellectual property rights arena.7 Prior to the Pfizer
case, the common approach of the Chinese pharmaceutical
industry to getting around drug patents was simply violating them
and creating infringing drugs to flood the Chinese market.8 The
approach of the Chinese companies in the Pfizer case suggests that
the Chinese are beginning to appreciate the value of patent laws.9
However, the case also exposes substantial limitations in the
Chinese patent law-although it seems that these limitations are
not necessarily of the character most often cited by foreign
in China Faces The Threat of Losing Its Patent on Viagra, ASIAN WALL ST. J., Nov. 29,
2002, at A4 ("Patent experts warn an adverse ruling poses a potential threat to the patents
of other foreign drug companies and will raise doubts about China's commitment to
international patent and intellectual property rights standards.").
4. Phelim Kyne & Leslie Chang, Glaxo Gives Up Patent, Avoiding Fight in China,
ASIAN WALL ST. J., Aug. 19,2004, at Al.
5. Id.
6. Pfizer filed an appeal of the decision of the China SIPO on September 28, 2004, in
the Beijing First Intermediate People's Court. Nicole Ostrow, Pfizer Appeals China's
Revocation of Viagra Patent, Sept. 28, 2004, (Update 3), http://quote.bloomberg.com/apps/
news?pid=10000080&sid=a7liUyLFeLwU&refer=asianews?pid=10000103&sid=az8zaBV
nPJOE&refer=us.
7. Peter K. Yu, Viagra's Upside: Rejecting Pfizer's Patent was a Sign of Progress in
China, IP LAW & BUSINESS US, Oct. 2004, at 49.
8. See id.; Yahong Li, The Wolf Has Come: Are China's Intellectual Property
Industries Prepared for the WTO?, 20 UCLA PAC. BASIN L.J. 77, 93-94 (2002).
9. Yu, supra note 7, at 49.
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pharmaceutical companies and U.S. trade representatives.'a
International drug and chemical companies eye the Chinese
market because of its size, but remain wary of the legal system and
criticize the weak protections afforded to pharmaceuticals by the
Chinese patent law system. For example, Rohm & Haas Co., E.I.
du Pont de Nemours & Co., and Eli Lilly & Co. all opefate within
China's borders, but have not been willing to establish
comprehensive research and development facilities in China."
Concerns about intellectual property protection also have kept
these companies from importing the most current technology into
the Chinese market." Nevertheless, increased competition in
China has resulted in a push to place some of the most current
pharmaceuticals in the Chinese market. 3
From one perspective, it seems odd that the patent laws that
currently exist in China do not adequately protect intellectual
property rights (IPRs): Chinese patent law is similar to the patent
laws of other WTO nations, having borrowed significantly from
both United States and European Union laws. 4 If the laws similar
to China's IPR laws are adequate to protect IPRs in the U.S. and
the EU, it seems these laws should per se be adequate to protect
IPRs in China. The failure of the laws to do so indicates China's
lack of commitment to IPR protection. Alternatively, it can be
argued that the recent cases of Chinese pharmaceutical companies
using China's patent laws to challenge foreign-held patents
indicates a new level of acceptance of China's IPR laws among
10. The U.S. government and business sector often characterize the limitations of the
Chinese patent law as the result of either an inept enforcement system or a failure of the
rule of law. See, e.g., Chris Buckley, China is Told Again to Open Markets, N.Y. TIMES,
Oct. 29, 2003, at W1 (quoting US Commerce Secretary Donald Evans, "When it comes to
intellectual property right protection [in China,] all observers would say they are not
there"); Sabra Chartrand, Stepping Up The Pressure Against Piracy in China, N.Y. TIMES,
Dec. 6, 2004 at C7; American Chamber Of Commerce - China, 2004 White Paper
Intellectual Property Rights, (2004), http://newfirstsearch.oclc.org.; Jeffrey Silva, Chamber
of Commerce Points out Problems with Chinese Wireless Pledge, RCR WIRELESS NEWS,
Sept. 16, 2002, at 17.
11. Shu Shin Luh, Let 100 Capitalists Bloom: China Pries Open Some of its Rules and
Regulations Ahead of the WTO Timetable, CORP. COUNS. (MAG.), Oct. 2003, at 132.
12. Id.
13. Id. (quoting Cherry Fan, in-house China counsel for Rohm & Haas in Shanghai,
"'Now competition [with other companies] is fierce. So how are we going to bring
technology that is new and targeted toward the Chinese consumers, but at the same time
protect ourselves against infringement?"').
14. See infra notes 22-26 and accompanying text.
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domestic businesses. From this perspective, the ability of China's
domestic businesses to realize direct benefits from China's patent
laws is necessary to the integration of intellectual property laws in
China's legal system.15
This article presents an argument for the latter perspective of
patent laws in China, asserting that while the concerns of foreign
pharmaceutical corporations regarding the protection of IPRs in
China are quite real and substantial, the recent cases involving
Pfizer and GlaxoSmithKine demonstrate the growing acceptance
and success of patent protection in China. Following this
perspective, concern over the domestic pharmaceutical industry's
use of the patent challenge procedure as a competitive tool, as in
the case of Viagra, is misplaced, as this type of business strategy is
commonplace in the U.S. and EU. Rather, attention should be
directed to refining China's patent laws so that disclosures made to
the China SIPO by foreign corporations cannot be used to
circumvent the patent process.
Part II of this paper includes a brief introduction to China's
patent law with a particular focus on the process of patent
invalidation that is currently affecting Pfizer in its attempt to
enforce patent rights in Viagra. The concept of intellectual
property rights did not develop organically in China, but rather
was introduced largely as a result of Western trade demands in the
twentieth century. Only by realizing a direct benefit from IPR
enforcement will the Chinese respect the laws enforcing IPRs. It is
precisely from such recognition of direct benefits from the
enforcement of IPRs that the concept of legal patents arose in the
West.
Part III of this paper presents the recent situation involving
the Chinese patent held by Pfizer and discusses how it
demonstrates an increased appreciation for patent law among
domestic businesses in China. Further, according to a proper
application of Chinese law, the outcome of the challenges to these
foreign-owned patents should be expected from the Chinese
patent system, and is not out-of-step with the decisions of other
countries regarding Pfizer's Viagra patent. As the domestic
pharmaceutical industry continues to grow in China, businesses
15. See, e.g., Peter K. Yu, From Pirates to Partners: Protecting Intellectual Property in
China in the Twenty-First Century, 50 AM. U.L. REV. 131, 207 (2000).
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will be increasingly incentivized to utilize the existing patent laws
both to protect their own inventions and as a strategic tool to
compete against foreign corporations.
II. A BRIEF INTRODUCTION TO CHINESE PATENT LAW
China is the oldest continuous civilization on Earth, dating
back nearly 5,000 years. However, despite the clear creativity and
inventiveness of the Chinese people,' the Chinese culture never
internally developed a concept of intellectual property rights. 7 The
reasons for this lack of an intellectual property concept seem to be
best explained by a complex interaction among the impact of
Confucianism throughout the history of China, the intellectual
preferences of the ruling classes of Imperial China, and the
historical lack of a developed merchant class that would need to
protect innovations while engaging in trade.18 Intellectual property
16. Striking examples of Chinese inventiveness include: gunpowder, paper, porcelain,
the magnetic compass, oil refining, the chain-drive transmission, the segmental arch
bridge, iron casting, the differential gear, the piston bellows, deep drilling, and the stirrup.
Rudi Volti, TECHNOLOGY, POLITICS, AND SOCIETY IN CHINA 15 (1982) (citing Joseph
Needham, Science and China's Influence on the World in Owen Dawson, THE LEGACY OF
CHINA 234-308 (1971)).
17. WILLIAM P. ALFORD, TO STEAL A BOOK IS AN ELEGANT OFFENSE:
INTELLECTUAL PROPERTY LAW IN CHINESE CIVILIZATION (1995); for a concise
discussion of the roots of the Chinese legal system as compared to the U.S. legal system,
see The Honorable Sam Hanson, The Chinese Century: An American Judge's Observations
of the Chinese Legal System, 28 WM. MITCHELL L. REV. 243, 249-252 (2001).
18. American legal commentators often attribute the absence of the concept of
intellectual property in Chinese society to Confucianism, the prevalent philosophy that
influenced China throughout much of its history. See, e.g., John R. Allison & Lianlian Lin,
The Evolution of Chinese Attitudes Toward Property Rights in Invention and Discovery, 20
U. PA. J. INT'L ECON. L. 735, 743-744 (1999); Jill Chiang Fung, Comment, Can Mickey
Mouse Prevail in the Court of the Monkey King? Enforcing Foreign Intellectual Property
Rights in the People's Republic of China, 18 LOY. L.A. INT'L & COMP. L.J. 613, 615 (1996);
Patrick H. Hu, "Mickey Mouse" in China: Legal and Cultural Implications in Protecting
U.S. Copyrights, 14 B.U. INT'L L.J. 81, 104 (1996); Peter K. Yu, Piracy, Prejudice, and
Perspectives: An Attempt to Use Shakespeare to Reconfigure the U.S.-China Intellectual
Property Debate, 19 B.U. INT'L L.J. 1, 17 (2001); Alexander C. Chen, Climbing the Great
Wall: A Guide to Intellectual Property Enforcement in the People's Republic of China, 25
AIPLA Q.J. 1, 8-10 (1997); Alford, supra note 17. However, it seems that attributing the
failure of an intellectual property concept in China to the dominance of Confucianism in
Chinese thought creates an overly-simplistic analysis. See Volti, supra note 16. Rather, it
may be appropriate to also consider that the isolationist attitudes that dominated the
governmental policy through most of Imperial China eliminated the development of a
merchantile economy of the type that created the necessity for patents and other
intellectual property rights in Europe. For excellent discussions of the development of
patents in the west, see F.D. Prager, The Early Growth and Influence of Intellectual
Loy. L.A. Int'l & Comp. L. Rev. [Vol. 28:1
laws in China thus did not evolve organically with Chinese society
but rather were exported, often through trade-associated political
pressure, from the West. 9
The current Chinese patent law was enacted in its basic form
in 1984.20 The original version of this law received strong criticism
for providing inadequate protection of IPRs in theory and in
practice, as the law was poorly enforced and penalties to patent
infringers were extremely small by Western standards.2'
Subsequent changes to China's intellectual property laws were
largely influenced by external pressures, most notably and
significantly from the U.S.22 Yet, the criticisms of Chinese law
structure and enforcement continue despite significant
Property, 34 J. PAT. OFF. SOC'Y 106, 107-108 (1952); M. Frumkin, The Origin of Patents,
27 J. PAT. OFF. SOC'Y 143 (1945).
19. See Zuolong Wu, Pharmaceutical Patent in the PR China: Adjustment in Public
Health Concern 9-13 (Autumn 2002) (unpublished master's thesis, Lund University),
available at http://www.jur.lu.se(InternetlEnglishlessayMasterth.nsfOI962236EAFDDF
60F3C1256C2300545401/$File/xsmall.pdf?OpenElement.
20. The first modern Chinese patent law actually dates to 1950 and the issuance of the
"Provisional Regulations on the Protection of the Invention Right and the Patent Right."
Louis S. Sorell, A Comparative Analysis of Selected Aspects of Patent Law in China and
the United States, 11 PAC. RIM L. & POL'Y J. 319, 321 (2002). However, this law was hardly
recognizable as a modern patent law, as it did not guarantee the right to exclude others
from the use of patented technology. See Chen, supra note 18, at 12. Not until the "Four
Modernizations" following the Cultural Revolution, was a new attempt made to create a
patent system in China. L. Harrington, Recent Amendments to China's Patent Law: The
Emperor's New Clothes?, 17 B.C. INT'L COMP. L. REV. 337, 343 & n. 35 (1994). In the
early 1980s, the Chinese government sent numerous envoys with legal, scientific, and
political backgrounds abroad to study the patent laws of various developed nations. Id. at
345. Based largely on the information gathered by these envoys, China enacted a basic
patent law in 1984. Id.
21. See generally Richard J. Ansson, Jr., International Intellectual Property Rights, the
United States, and the People's Republic of China, 13 TEMP. INT'L COMP. L.J. 1, 10-11
(1999); Glen R. Butterton, Pirates, Dragons and US International Property Rights in
China: Problems and Prospects of Chinese Enforcement, 38 ARIz. L. REV. 1081, 1093-1105
(1996); Jeffrey W. Berkman, Intellectual Property Rights in the P.R.C.: Impediments to
Protection and the Need for the Rule of Law, 15 UCLA PAC. BASIN L.J. 1, 14-37 (1996).
22. For discussions of the U.S. pressures on China that forced changes to Chinese
intellectual property laws in 1992, 1994, and 1996, see Frank J. Garcia, Americas
Agreements-An Interim Stage in Building the Free Trade Area of the Americas, 35
COLUM. J. TRANSNAT'L L. 63, 128 n.324 (1997) (explaining that "Special 301 ... requir[es]
the United States Trade Representative to identify countries which deny adequate and
effective protection of intellectual property rights, and designate those countries for
investigation and possible retaliation... "); see also Dennis S. Fernandez, China's IP Is
Not Entirely Out of the Haze Yet, 10 No. 6 INTELL. PROP. STRATEGIST 1 (2004); Naigen
Zhang, Intellectual Property Law Enforcement in China: Trade Issues, Policies and
Practices, 8 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 63,72 (1997).
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modification of legal practices concerning IPRs.23 Nevertheless,
because of the significant influence of the U.S. in shaping Chinese
IPR policy, China Patent Law has many elements that should be
familiar to U.S. practitioners.24
Despite the current structural and enforcement problems
involving IPRs, China's intellectual property law in general and
patent law in particular have evolved tremendously within a
relatively brief period of time.25 It is important to realize that-
particularly in the case of patent law-the current structure of
intellectual property law in China is of foreign origin.26 It will take
time before these laws, which not only did not develop organically
within the Chinese legal system but also conflict with thousands of
years of cultural history, are integrated into modern Chinese legal
and economic culture. Nevertheless, there are indications that
Chinese businesses are adopting a new way of doing business that
uses intellectual property laws strategically rather than simply
violating the intellectual property rights of foreign businesses. One
such area of business is in the Chinese pharmaceutical industry.
The changes in the attitude toward patent law in China can be
seen in the ongoing attempt of twelve Chinese pharmaceutical
companies to invalidate Pfizer Corp.'s Viagra patent in China.27
III. CHINA'S PROGRESS ON THE ROAD TO IPRs IS EXEMPLIFIED IN
PHARMACEUTICALS
The protection of intellectual property rights is the most
extensive in the West, especially in the U.S. In the United
Kingdom and in its legal cousin the United States, as well as in
continental Europe, patent and other intellectual property laws
developed organically within the respective legal systems rather
23. See Assafa Endeshaw, A Critical Assessment of the U.S. - China Conflict, 6 ALB.
L.J. ScI. & TECH. 295, 309-35 (1996).
24. See generally, Louis S. Sorell, A Comparative Analysis of Selected Aspects of
Patent Law in China and the United States, 11 PAC. RIM L. & POL'Y J. 319, 321 (2002).
25. Endeshaw, supra note 23, at 299 (noting that China adopted the entire gamut of
intellectual property rights laws in a decade).
26. See Allison & Lin, supra note 18.
27. Audra Ang, Chinese Companies Hoping to Copy Viagra, BOSTON GLOBE, Dec. 6,
2002, at A40, available at 2002 WLNR 2594224.
28. See generally, Ruth Gana Okediji, Copyright and the Public Welfare in Global
Perspective, 7 IND. J. GLOBAL LEGAL STUD. 117 (1999); Dru Brenner-Beck, Do As I Say,
Not As I Did, 11 UCLA PAC. BASIN L.J. 84 (1992).
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than being imposed from outside legal systems." It is not
coincidental that collectively, citizens of these countries realize
substantial benefits from the enforcement of IPRs-the perceived
value of IPRs provided the impetus for those very laws that
protect the economic interests in those intangible rights.30
In contrast to the West, citizens of the PRC are only
beginning to realize the economic benefits that attach to IPRs.
With the reforms of the -1990s, the winds of economic change are
bringing an awareness of the value of intellectual property.
31
Initially, as seen by the rampant counterfeiting and piracy of
copyrights and trademarks, many Chinese businesses recognized
only the value of intellectual property that belonged to foreign
investors. 2 Increasingly, however, Chinese businesses recognize
the benefit to their own economic interest that can be gained
through the use of intellectual property laws.
To see the effect of this trend, consider China's
pharmaceutical industry. PriceWaterhouseCoopers estimated that
in 2000, China's pharmaceutical industry was worth $28.2 billion
(approximately 2.8 percent of GDP).33  In 2002, China's
pharmaceutical industry experienced a 15.5 percent rate of growth,
with a 22 percent growth in profits.34 The central government is
29. See Frumkin, supra note 18, at 144-48; Prager, supra note 18, at 107-08.
30. The early concept of intellectual property in Europe, dating to the sixteenth
century, coincided with the movement of skilled artisans from one locale to another
throughout the Continent, often attracted by a local government or monarch, and the
need of these artisans to protect the secrets of their trade. See Prager, supra note 18 at 108.
It seems clear that the concept of intellectual property would not have been so important
at the time were it not for the increase in trade and the merchant class during the
European renaissance. See id.; see generally Frumkin, supra note 18.
31. See, e.g., Jeffrey W. Berkman, Intellectual Property Rights in the P.R.C.:
Impediments to Protection and the Need for the Rule of Law, 15 UCLA PAC. BASIN L.J. 1,
16-17 (1996); Jianyang Yu, People's Republic of China: Protection of Intellectual Property
in the P.R.C.: Progress, Problems, and Proposals, 13 UCLA PAC. BASIN L.J. 140, 140
(1994); Naigen Zhang, Intellectual Property Law in China: Basic Policy and New
Developments, 4 ANN. SURV. INT'L & COMP. L. 1, 1 (1997).
32. Daniel C.K. Chow, Counterfeiting in the People's Republic of China, 78 WASH. U.
L.Q. 1 (2000); Anglea Mia Beam, Comment: Piracy of American Intellectual Property in
China, 4 J. INT'L L. & PRAC. 335, 336 (1995).
33. Allan Zhang, The Future of China's Pharmaceutical Industry (2001),
http://www.pwc.com/extweb/newcolth.nsf/docid/4CE903FAD5FB1DF985256A31007820C
B (last visited Feb. 24, 2005).
34. China Industry Development Report, http://wwwl.cei.gov.cnlce/e reportl
hy/yy.htm (last visited Feb. 18, 2005) (summarizing China's Pharmaceutical Industry in
2003).
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currently putting money into the pharmaceutical industry,
specifically to encourage domestic research and development.35
With increasing profits and opportunity at stake, the Chinese drug
companies that once built businesses around pirating foreign-
owned pharmaceuticals are now beginning to use intellectual
property laws as a strategic tool.36 This shift in business practice is
significant because it demonstrates that the enforcement of IPRs
can provide a profitable business environment for Chinese
businesses. A recent example of this shift is the well-publicized
invalidation of Pfizer's Chinese patent on Viagra by SIPO. While
criticized extensively by U.S. businesses and the U.S. trade officials
as a sign that China lacks the interest in enforcing intellectual
property laws and in complying with TRIPS, the case really
provides an important example of the growing acceptance of IPRs
in Chinese business culture.
A. The Case of Pfizer's Viagra Patent in China Draws Criticism
from the International Community
While official reports of Chinese patent cases and
administrative actions are often not published and are therefore
difficult to obtain, the progress of Pfizer's recent high-profile
troubles with their Chinese patent on Viagra suggest that Chinese
patent law is well on its way to comporting with international
standards.
1. The invalidation of Pfizer's Viagra patent.
On May 13, 1994, Pfizer submitted an application for a patent
entitled "Pyrazolopyrimidinones for the treatment of impotence"
with the China SIPO.38 On that same day, Pfizer submitted patent
applications of the same name with, inter alia, the United States
Patent and Trademark Office (U.S. PTO)39 and the European
35. China Internet Information Center, China's Pharmaceutical Industry Gets Major
Push, Apr. 24, 2002, http://service.china.org.cn/link/wcm/ShowText?infoid=31451&
p-qry=pharmaceutical.
36. Yu, supra note 7.
37. See American Embassy in China, IPR: Patent, http://www.usembassy-
china.org.cn/ipr/patent.html (last visited Nov. 28, 2005).
38. China patent application number 94,192,386, publication number 1,124,926 (filed
May 13, 1994), available at http://www.sipo.gov.cn/sipo-English/zljs/default.htm.
39. U.S. Patent Application No. 549,792 (filed May 13, 1994).
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Patent Office.0 Pfizer considered these applications to be the basic
patents covering the male erectile dysfunction drug Viagra;
41
however, none of the applications claimed the invention of
sildenafil citrate, the drug's active ingredient. Instead, the
applications claimed the use of this previously-known compound
and its close variants for the preparation of a medical treatment
for erectile dysfunction in a male animal.42
The State Drug Administration (SDA) approved Viagra for
use in China on July 2, 2000.43 The pre-patent version of the drug
was marketed in China under the Chinese-language brand name
Wan Ai Ke after a four-year wait for approval." Access to the
drug was limited to prescriptions from senior physicians in hospital
urology departments, and dispensing was restricted to hospital
pharmacies. The drug was produced entirely at a pharmaceutical
factory in Dalian, a city in Northeast China's Liaoning Province,
and distributed exclusively by a local company, CNCN.4
The promise of the potential Chinese market for Viagra
attracted the attention of local drug manufacturers, both legitimate
and counterfeit. By May of 2000, a "well-known but unidentified"
pharmaceutical company in China's Guangdong Province was
manufacturing sildenafil citrate, the active ingredient in Viagra.47
The company (presumably) relied upon the disclosures Pfizer
made to the China SIPO in applying for a sildenafil citrate gatent
as a foundation for their research and development, and
40. European Patent Office No. EP 0 702 555 B1 (filed May 13,1994).
41. In press releases from Pfizer and reports from the press, this patent has been
referred to as Pfizer's "Viagra patent."
42. U.S. Patent No. 6,469,012 B1 (filed May 13, 1994) (issued Oct. 22, 2002);
European Patent Office No. EP 0 702 555 B1 (filed May 13, 1994).
43. China Grants Pfizer Patent for Viagra, CHINA ONLINE, June 7, 2001, available at
LEXIS, News Library.
44. Phelim Kyne, Pfizer Patent on Viagra in China is Scrutinized During Hearings,
ASIAN WALL ST. J., Sept. 5, 2002, at M8.
45. Shi Pengyun, Viagra No Longer Hard to Get, CHINA DAILY, Feb. 7, 2002,
available at http://www.chinadaily.com.cn/en/doc/2002-02/07/content-1.05885.htm.
46. Id.
47. More to Love: Chinese Co. Creates Viagra Substitute, CHINA ONLINE, May 23,
2000, available at LEXIS, News Library. This company is likely The Biochemical
Pharmaceutical Factory of Zhuhai SEZ, listed as applicant of a patent application number
00804991 entitled "Process for preparing sildenafil, and troche which comprises sildenafil
and apomorphine and its prep," dated June 8, 2000 and published February 26, 2003.
48. The China SIPO database lists "Pfizer Research And Development Co., N. V. / S.
A." as the applicant of a patent entitled "Process for preparing sildenafil," application
(Vol. 28:1
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developed a method of extracting and synthesizing sildenafil
citrate that differed from the method claimed by Pfizer, and
applied for its own patent with the China SIPO. 49 While this
"Guandong Viagra" was required to undergo clinical trials before
it could be sold commercially, ° pressures on Viagra market share
increased through the prevalence of counterfeit drugs sold in sex-.51
shops, airports, and pharmacies throughout China. Pfizer was
able to combat some of the market pressure by entering into
agreements with the Chinese government to combat counterfeit
pharmaceuticals5 2 and by securing an expansion of the official
channels through which Viagra could be distributed. 3
Pfizer received a "Notification to Grant Patent" from the
China State Intellectual Property Office (SIPO) in early June,
2001. 54 The final patent was issued on September 19, 2001."5 That
same day, a group of twelve Chinese drug companies petitioned
the Patent Reexamination Board to invalidate Pfizer's patent.56
number 97113261 dated June 13, 1997 and published December 12, 1997. See
http://www.sipo.cn/English.
49. More to Love, supra note 47.
50. Id.
51. See Shi, supra note 45 (quoting the chief physician in urology at the First Hospital
Attached to Peking University as stating, "all medicine with the name 'Viagra' for sale in
drugstores are fake"); China Passes Law to Combat Counterfeits, CHEMICAL Bus.
NEWSBASE, Sept. 4, 2002, at P10, available at 2002 WL 26164177; Kyne supra note 44
(noting that numerous counterfeit versions of Viagra sold at sex-oriented shops and at
airports under the name "Weige" or "great man"); Ang, supra note 27 (citing the official
Xinhua News Agency statistic that after six months on the market, some 90 percent of
Viagra pills sold in Shanghai were counterfeit).
52. Pfizer Signs Agreement with Shanghai Government to Enhance Protection of
Patients, Pfizer Inc. Press Release May 18, 2004, available at
http://www.pfizer.com/are/newsreleases/2004pr/mn_2004_0518.html (announcing the
signing of a memorandum of understanding that allowed Pfizer to provide Chinese
officials with, inter alia, anti-counterfeiting training).
53. See Shi, supra note 45
54. China grants Pfizer patent for Viagra, supra note 43.
55. Kyne supra note 44.
56. Id. There are notable discrepancies regarding the actual number of Chinese
pharmaceutical companies that initiated or participated in the re-examination petition
against the Pfizer patent. The reported number ranges from "over ten" (Delia Liu, China
Drug Cos Tie Up to Make Viagra Variant After Pfizer Loses Patent, XINHUA FIN.
NETWORK (XFN) NEWS, AUG. 5, 2004) to twelve (Id.; Ang, supra note 27; Guo Nei,
Viagra Patent Found Invalid, CHINA DAILY, July 9, 2004, available at
http://www.chinadaily.com.cn/english/doc/2004-07/09/content_346788.htm to thirteen
(Pfizer- China challenges Viagra patent, loses US appeal against Apotex, CHEMICAL BUS.
NEWSBASE, Feb 13, 2003, at P31) to "up to 15" (China's IP officials still considering
appeal against Pfizer's Viagra patent, XINHUA FIN. NETWORK (XFN) NEWS, Apr. 13,
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Under Chinese law, once an announcement of a grant of patent
rights is made, any interested entity or individual can petition the
Patent Reexamination Board to reexamine the patent and declare
the patent invalid.57  The challenging coalition included
Hongtaomao Pharmaceutical Co. Ltd., Lianxiang Pharmaceutical
Co. Ltd.,58 and Shuanglong Hi-tech Development Co. Ltd.59 Some
reports indicated that the mid-size companies had been refused
patent protection for their own erectile-dysfunction drugs with a
chemical composition similar to Viagra. 6° The strategy to challenge
the patent in the Patent Reexamination Board, rather than to
simply counterfeit the drug or otherwise infringe the patent, was a
new approach to competing with foreign products. The relatively
small Chinese pharmaceutical companies filing the re-examination
petition view the procedure as an opportunity to "leapfrog" the
long and costly research, development, and approval process that
is required to bring a new drug to market.61 According to a
2004) to "more than 20" (Pfizer Asks[sic] the Patent of Viagra, SINOCAST CHINA BUS.
DAILY NEWS, Dec. 4, 2002, at 8).
57. Zhonghua Renmin Gongheguo Zhuanli Fa [Patent Law of the People's Republic
of China] 12 P.R.C. LAWS 173 (adopted Aug. 25, 2000) [hereinafter China Patent Law],
Art. 45 ("Where, starting from the date of the announcement of the grant of the patent
right by the patent administration department under the State Council, any entity or
individual considers that the grant of the said patent right is not in conformity with the
relevant provisions of the Law, it or he may request the Patent Reexamination Board to
declare the patent right invalid."). The Patent Reexamination Board is created under Art.
41 of the China Patent Law ("The patent administration department under the State
Council shall set up a Patent Reexamination Board ... ") and has sole jurisdiction over
challenges to patent invalidity. The panel consists of three to five members, where five
members are used if the case has great impact on China or abroad, involve important or
complex legal issues, or involves large economic interests. Haitao Sun, Note, Post-Grant
Patent Invalidation in China and in the United States, Europe, and Japan: A Comparative
Study, 15 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 273, 288 (2004). The acceptable
grounds for initiating a reexamination procedure are set-out in Implementing Regulations
of the China Patent Law, Rule 64(2) (2001).
58. Kyne, supra note 3.
59. Duan Hongqing et al., China Revokes Viagra Patent, CAIJING ENGLISH
NEWSLETTER, July 22, 2004, available at http://www.caijing.com.cn/English/2004/
040720/040720viagra.htm.
60. Kyne, supra note 44; Shi, supra note 45. It is, however, unclear what is meant by
this statement in the press. Pfizer's Chinese patent did not protect the composition of
Viagra, only the "use" of the drug sildenafil citrate for the treatment of male erectile
dysfunction. Thus, the scope of the patent reportedly applied for by these companies is
uncertain and a reliable report on this point cannot be located.
61. Kyne, supra note 44 (citing comments made by Cui Xiaoguang, president of the
legal firm Beijing Sanyou Intellectual Property Agent Ltd., "If you completely imitate
foreign medicines, it will save you a lot of money in obtaining the approval of medicine
2006] Viagra & Patent Protection in China 13
statement from Lianxiang Pharmaceutical, the basis for the
challenge to Pfizer's patent was the patent's ability to meet the
novelty requirement under China's patent law.62
On July 7, 2004, the Patent Reexamination Board announced
its decision to invalidate Pfizer's Viagra patent.63 A full written
decision was not released at that time.64 However, one Chinese
news source reported the language released by the Patent
Reexamination Board at the time the Pfizer decision was
announced:
In view of the technical descriptions in the specifications of the
disputed patent and available technologies in the field
concerned, it is impossible to confirm that the compound can
cure or prevent erectile dysfunction of male animals without the
creative labor of technical personnel in the filed concerned.
Therefore, the technical openness in the patent specification is
incompatible with the claims to rights, i.e. the disputed patent
does not confirm to the provisions in Clause 3 of Article 26 of
China Patent Law. Therefore, the patent is declared invalid.65
Such assertions concerning the Patent Reexamination Board's
language are in accord with the reports from other sources.66
because you have some [foreign] data.., so you may get the approval from the drug
administration without much investment. These small companies don't want to spend
much money, and hope the patent will be declared null and void.").
62. See Chinese Companies Challenge Viagra Patent, TAIPEI TIMES, Dec. 9, 2002, at
12, available at http://www.taipeitimes.comNews/worldbiz/archives/2002/12/09/186551. For
a discussion of the meaning of "novelty" under China Patent Law, see infra notes 153-157
and accompanying text.
63. Gardiner Harris, Pfizer Reports China has Lifted its Viagra Patent, N.Y. TIMES,
July 8, 2004, at C1. Invalidated patents are deemed non-existent from the beginning, as if
the patent were never issued. China Patent Law, supra note 57, Art. 47.
64. Harris, supra note 63.
65. Stone Xu, An In-depth Look at Viagra's Abrupt Change of Fate in China, CHINA
IP (HURRYMEDIA), Sept. 28, 2004 (on file with author) (quoting the No. 6228 Invalidity
Claim Decision of the Patent Reexamination Board). Clause 3 of Article 26 of China
Patent Law (2000) states: "The specification shall describe the invention or utility model in
a manner sufficiently clear and complete so that a person skilled in the relevant field of
technology can accurately produce it .... " China Patent Law, supra note 57.
66. E.g., Paul Mooney, China challenging drug patents, THE SCIENTIST, Aug. 20,
2004, http://www.biomedcentral.com/news/20040820/02 (stating that a Chinese-language
document on SIPO's web site stated that the Patent Reexamination Board revoked
Pfizer's patent for insufficient disclosure, indicating that the patent application had failed
to accurately explain the use of Viagra's key ingredients); Liu Li, Patent on Viagra Faces
Challenge, CHINA DAILY, Sept. 29, 2004, available at http://www.chinadaily.com.cn/
Englishldoc/2004-09/29/content_378513.htm (reporting that the Patent Reexamination
Board held the patent to be invalid because it did not conform to the patent application
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According to Cao Jinyan, Vice President of the Patent Research
Development Center of SIPO, Pfizer failed to fulfill the disclosure
requirements in the patent application; thus, the invention could
not be reproduced by experts based solely on the information
provided in the patent application. 67
Pfizer filed a petition for reconsideration directly with the
SIPO on September 8 and an appeal of the Patent Reexamination
Board's decision with the Beijing First Intermediate People's
Court on September 28. 68 Pfizer claimed in its appeal that the
Patent Reexamination Board unfairly applied a higher disclosure
standard for the patent application during reexamination than was
in effect at the time Pfizer submitted the application.69 Pfizer has
the right for one additional appeal to the High People's Court if
the decision of Patent Reexamination Board is not reversed at the
intermediate court level.70 Each appeal could take up to three
disclosure requirements under China Patent Law, Art. 26 (2000)); Ostrow, supra note 6
(reporting that the Patent Reexamination Board had determined that Pfizer had not
provided full documentation in the patent application showing that Viagra's key
ingredient sildenafil citrate was the primary factor in preventing erectile dysfunction).
67. Mooney, supra note 66.
68. Phelim Kyne, Pfizer To File China Viagra Appeal Tue, Dow JONES CHINESE FIN.
WIRE, Sept. 28, 2004. The decision of the Patent Reexamination Board is subject to
judicial review by the First Beijing Intermediate People's Court. PETER FENG,
INTELLECTUAL PROPERTY IN CHINA 245 (2d ed. 2003). The court reviews Patent
Reexamination Board decisions de novo and the Patent Reexamination Board has the
burden of proof to demonstrate that its invalidation decision was proper. See Hanson,
supra note 17 at 251; Albert P. Melone, Judicial Independence in Contemporary China, 81
JUDICATURE 257, 258 (1998). The party seeking judicial review must file the
appropriate petition within three months of the PRD decision. Patent Law, Art. 46, 12
P.R.C. LAWS 173 (adopted Aug. 25, 2000). The court will uphold the decision of the
Patent Reexamination Board if: (a) the evidence relied upon is conclusive; (b) the
application of the law and regulations are correct; and (c) the legal procedures are
complied with. Benjami Bai & Helen Chang, Are Your Chinese Patents at Risk?, INTELL.
PROP. TODAY, Oct. 2004, available at http://www.jonesday.com/pubs/
pubs-detail.aspx?publD=S1766.
69. Matthew Forney, Patent Denied: Erectile Dysfunction is Big Business in China,
TIME MAG. ASIA, July 19, 2004, available at http://www.time.com/time/asia/
magazine/article/0,13673,501040719-662829,00.html. Pfizer's argument on appeal seems to
have been adopted for political purposes by the U.S. when commenting on its position on
trade with China. U.S. Commerce Secretary Donald L. Evans stated in a speech given at
the U.S. Embassy in Beijing that "[a]fter initially approving Viagra for sale in China, the
Patent Review Board later applied a new law retroactively to deny Pfizer's patent." Press
Release, State Department Press Releases & Documents (Jan 13, 2005), available at 2005
WL 58694563.
70. Zhonghua Renmin Gongheguo Fayuan Zuzhifa [Organic Law of the People's
Courts of the People's Republic of China] [hereinafter Organic Law of the People's
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years to complete;71 during this time, Pfizer's patent would remain
valid, bringing Pfizer within four years of its 2014 patent expiration
date.
2. The Fallout of the Viagra Patent Invalidation.
Long before the Patent Reexamination Board's
reexamination decision on the Viagra patent, Pfizer and the U.S.
government positioned themselves to respond to the expected
invalidation. In numerous statements to the press, both Pfizer and
the U.S. government linked the future of American trade with the
Chinese, as well as China's successful integration into the World
Intellectual Property Organization (WIPO), with the outcome of
the Pfizer case. For example, an unnamed "Western diplomat" was
quoted in the Asian Wall Street Journal as stating, "I think it
would have serious repercussions for the Chinese if the Pfizer
patent was not upheld [and] it will really raise the question in the
international community, drug makers as well as their
governments, if SIPO is prepared and has the proper tools to make
these decisions."72 Trade officials from the U.S. also watched the
Pfizer reexamination closely and "Deputy U.S. Trade
Representative Josette Sheeran Shiner in November called the
Chinese companies' challenge of Pfizer's Viagra patent a
'particularly troubling' example of China's questionable
commitment to intellectual-property rights.
73
The political posturing intensified upon SIPO's
announcement of its decision to invalidate the patent. Richard
Mills, the spokesman for the U.S. trade representative, told the
New York Times, "It's difficult not to view this case within a
pattern of intellectual property infringement. . .. [The United
Courts], Art. 12 1 (1983) ("In the administration of justice, the people's courts adopt the
system whereby the second instance is the last instance"); Mooney, supra note 66. Pfizer
will almost certainly be using its second appeal of right. From January 1989 to December
1998, the Beijing Intermediate People's Court has received 63 appeals of Patent
Reexamination Board decisions to invalidate a patent; 56 of those cases have been decided
and the court has decided against the Patent Reexamination Board in only nine of those
cases. Jiang Zhipei, Patent Litigation in China, n.7 (Sept. 13, 1999),
http://www.chinaiprlaw.com/english/forum/forum4.htm#6.
71. See Stone Xu, An In-depth Look at Viagra's Abrupt Change of Fate in China,
CHINA IP (HURRYMEDIA), Sept. 28, 2004; Mooney, supra note 66.
72. Kyne, supra note 3.
73. Phelim Kyne, China Overturns Pfizer's Patent for Viagra Drug, ASIAN WALL ST.
J., July 8, 2004, at Al.
20061
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States will] be discussing this and other intellectual property issues
with the Chinese. 7 4 One Western diplomat warned that the U.S.
and the EU could retaliate for the SIPO decision with trade tariffs
aimed at China's domestic pharmaceutical industry. 5 The
American Chamber of Commerce stated that "[t]he June 5, 2004,
decision by SIPO to invalidate Pfizer Inc.'s use patent for Viagra..
• has caused great concern, extending beyond the pharmaceutical
industry to the entire business community."76 Pfizer Chairman and
Chief Executive Officer Henry McKinnell noted that regarding the
decision, "[The company is] extremely disappointed. The basis of
fair trade is respecting intellectual property."77 More importantly,
McKinnell indicated that the decision "absolutely" could dissuade
Pfizer from further investments in China.78
Despite the pronouncements of the U.S. trade office and the
U.S. pharmaceutical industry, it is unclear whether the SIPO
decision, even if upheld in appeal to the People's Court, is
indicative of anything but China's progress toward adopting the
intellectual property standards established by the WTO through
TRIPS. Nevertheless, only a small handful of practitioners noted
this significance in the Viagra patent reexamination. For instance,
Gao Jun, a patent attorney with Duan & Duan Law Firm in
Shanghai, noted that the Viagra patent reexamination indicated
improvements in China's patent protection." "In years past, no
one would even waste time on such legal battles. . .. Factories
would rather start production of counterfeited or imitate
medicines immediately."80 Professor Peter Yu of Michigan State
University College of Law expressed a similar perspective,
commenting that "the Viagra decision was exactly what the
holders of IP rights should expect in a country making the.
transition to full compliance with the WTO agreements., 81 A
partner at the Shanghai office of a United Kingdom-based
intellectual property law firm also pointed to the administrative
challenges to drug patents in China as indicia of Chinese
74. Harris, supra note 63, at C4 (quoting Richard Mills).
75. Kyne, supra note 73.
76. American Chamber of Commerce - China, supra note 10.
77. Lloyd-Smith, supra note 2.
78. Id.
79. Ang, supra note 27.
80. Id.
81. Yu, supra note 7.
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companies using the patent system as a strategic business tool.
82
The Chinese pharmaceutical industry was quick to take
advantage of their initial legal victory in the Viagra patent dispute
and revealed the next step in their strategy for competing against
Pfizer for the erectile dysfunction drug market. Shortly after news
of the SIPO decision became public, a group of seventeen Chinese
pharmaceutical manufacturers announced their plan to establish a
joint-stock company to produce an erectile dysfunction drug
similar to Viagra. 83 By early October, 2004, the joint venture had
established an office in Beijing and had invested the shareholders'
capital in the new company.8' The primary goal of this joint
venture, according to Zhang Yucai, chairman of Tonghua
Hongtaomao Pharmaceutical Co. Ltd., was to jointly promote the
domestic "Viagra" while avoiding a price war with each other.85
The joint venture had received authorization for the "Chinese
Viagra" by the State Food and Drug Administration in October
2004 and is awaiting the required production license.86 However, it
is unlikely that the production license will be granted within a
year:87 the State Food and Drug Administration may choose to
withhold a production license until the status of the Viagra patent
88is finalized by the courts. If "Chinese Viagra" does eventually
reach the market in China, it will be a formidable competitor for
Pfizer because the Chinese alliance plans to sell their drug for 40
to 50 yuan per tablet, while the current price for Pfizer's Viagra in
81China is 99 yuan per tablet.
While the Chinese pharmaceutical industry was enthusiastic
about their initial victory in the SIPO over the Viagra patent, some
82. Phelim Kyne & Leslie Chang, Glaxo Gives Up Chinese Patent Amid Drug
Makers' Challenge, WALL ST. J., Aug. 19, 2004, at B6 (quoting attorney Douglas Clark of
the law firm Lovells as stating, "The Chinese drug companies are starting to take the law
seriously.., trying to invalidate patents rather than just infringing them.").
83. Delia Liu, China Drug Cos Tie Up to Make Viagra Variant After Pfizer Loses
Patent, XINHUA FIN. NETWORK (XFN) NEWS, AUG. 5,2004.
84. Jia Hepeng, Chinese Drug Firms Ally Against Pfizer, BUS. WKLY. (CHINA




87. Id. (citing Sun Mingjie, chairman of Guangzhou Viaman Pharmaceutical Co.
Ltd.).
88. Id. (citing Wang Fei, a lawyer in the Beijing Huake Intellectual Property Firm).
89. Mooney, supra note 66.
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foreign companies began to express their less-than-optimistic
views of the Chinese intellectual property environment through
their actions. Most notably, GlaxoSmithKline abandoned a
defense of its formulation patent for rosiglitazone, the key
ingredient of its popular Type 2 diabetes drug Avandia.4
GlaxoSmithKline's patent, issued in July 2003," was challenged by
Chinese companies Shanghai Sunve Pharmaceutical Co. Ltd.,
which has a joint venture with Swiss-based Roche Holding AG,
Chongqing Taiji Industry (Group) Co. Ltd., and Zhejiang Wanma
Pharmaceutical Co. Ltd. The challenge to Glaxo's patent, like the
challenge to the Viagra patent, centered on the issues of novelty
and inventiveness;93 the Chinese plaintiffs asserted that some of the
elements protected by the patent were already published in the
public domain before the patent took effect. 94 The Chinese patent
system requires absolute novelty with regards to publication of an
invention for the issuance of a valid patent.95 In addition, because
China implemented a "first to file" system similar to the European
patent systems rather than the unique "first to invent" priority
system found in U.S. patent law, issues of novelty like the one that
faced Glaxo are extremely difficult to circumvent.
90. Kyne & Chang, supra note 82.
91. Patent Application No. 98805686, covering 2 to 8 milligrams Rosiglitazone or its
pharmaceutically-acceptable salts. Jia Hepeng, Drugmakers Wrestle Over Medicine
Patents, CHINA DAILY, Aug. 17, 2004, available at http://www.chinadaily.com.cn/
English/doc/2004-08/17/content_366249.htm.
92. China Firms Challenge GlaxoSmithKline Drug Patent, BUS. DAILY UPDATE
(CHINA DAILY), Aug. 2, 2004, available at LEXIS, News Library; Pharmaceutical
Company Gives Up Chinese Patent on Popular Diabetes Drug, DRUG WK., Sept. 10, 2004,
at 523, available at LEXIS, News Library.
93. Glaxo Withdraws Patent Defense in China, CHINA BUSINESS PRESS, Sept. 8, 2004,
available at http://www.uscbp.comi/NewsDetails.aspx?newsid=176. Xu Gouwen, the lawyer
who represented the Chinese drug companies, stated, "Glaxo's patent for rosiglitazone,
the core intergradient [sic] of Avandia, has no creativity and no novelty [... ] One year
before Glaxo's patent application, as early as 1995, the Journal of Clinical Pharmacology
published two articles in September and November issue [sic] respectively, elaborating on
the effectiveness of 4-mg and 8-mg rosiglitazone for curing diabetes." Id.
94. Kyne & Chang, supra note 82.
95. China Patent Law, Art. 22 & 23 (2000). This requirement is in contrast to the U.S.
system, which allows for a one-year grace period between the prior public disclosure in the
United States and the patent application date. 35 U.S.C. § 102(a), (b) (2005).
96. China's "first to file" priority requirement is established in China Patent Law,
Art. 22 & 23 (2000). The law does allow for a grace period in China Patent Law, Art. 24
(2000), whereby an invention "does not loose its novelty where, within six months of the
filing date, one of the following events occurred: (1) where it was exhibited at a Chinese
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Nevertheless, despite the dire predictions expressed in public
by foreign corporations and Western diplomats, and especially
despite Pfizer's threat to stop investing in China, Pfizer announced
the establishment of a new regional headquarters in Shanghai and
the founding of the Pfizer Investment Holding Company.97 The
formation of this holding company, with a registered capital of
US$175 million, signifies a significant commitment to the Chinese
market by Pfizer.98 The Chinese pharmaceutical market simply has
too much growth potential for Pfizer to ignore. 99 And despite the
rhetoric in the media, Pfizer must also clearly recognize that the
China SIPO reexamination decision was neither per se
unreasonable nor not out-of-step with the decisions reached by
other foreign patent systems.
B. "Chicken Little" Go Home: The Recent Petitions to Invalidate
Pharmaceutical Patents Exemplify China's Progress Toward
Acceptance of IPRs.
Chinese companies are beginning to rely on patent law as part
of their business strategy for addressing competition from foreign
corporations.'0° The patent invalidation petitions against Pfizer and
GlaxoSmithKline, both successful in different ways, exemplify this
trend. While the two companies publicly deny any relationship
between the two cases, pharmaceutical industry analysts believe
that the two cases are similar in their role of encouraging more
Chinese drug makers to utilize the patent laws rather than outright
government exhibition, (2) where it was first made public in an academic or technological
meeting; (3) where it was disclosed without the consent of the applicant." Id. Outside
these narrow exceptions, it is very difficult to defend against a valid challenge on the basis
of novelty in a first-to-file priority system. The prior art is either present or it is not, and
the only defense to the challenge is found in asserting that the patent at issue does not
read on the alleged prior art. In the U.S. "first to invent" system, within certain limits, the
patentee has the additional defense of "swearing behind" the prior art-i.e. submitting
proof that he first conceived of the invention and exhibited reasonable diligence between
the time of conception and reduction to practice. 35 U.S.C. § 102 (g) (2005).
97. Hu Yan, Pfizer China Takes Giant Step in Local Market, CHINA DAILY, Oct. 30,
2004, available at 2004 WLNR 11949113.
98. See id.
99. Bruce Einhorn et al., Go East, Big Pharma, Bus. WK., Dec. 13, 2004, at 28.
100. Zhu Shen, Unleash The Dragon, PHARMACEUTICAL EXECUTIVE, Dec. 1.2004, at
82 (citing Tony Chen, head of the China IP practice group in the Shanghai office of Paul,
Hastings, Janofsky & Walker LLP).
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infringement to expand domestic markets for generic medicines.1 1
The invalidation proceedings concerning Viagra and Avandia
patents are partly the result of the rapid growth of the patent
system in China.'O It is currently estimated that 97 percent of
China's pharmaceuticals are generic copies of foreign drugs.'03
Much of the copying of non-patented drugs began in the late 1980s
and early 1990s, when China's patent protections were, in general,
relatively weak and pharmaceutical inventions were not
patentable, but foreign pharmaceutical companies began investing
in ChinaP 4 In that climate, Chinese drug makers invested in drug
copying work;05 but through the 1990s, patent protection became
stricter in China, and in 2000, China revised its patent law to
comply with WTO requirements. Now that China's patent laws are
relatively strong and are largely consistent with the WTO
standards, Chinese drug makers are faced with a choice among:
patent infringement risks; loss of investment and product; and
bringing reexamination petitions to invalidate the foreign-owned
patents.'°6
101. Jia, supra note 91. Hou Dakun, president of Beijing KevinKing Management
Consulting Co Ltd is quoted as stating "[tihe number of cases will definitely increase, as
more and more domestic drugmakers try to break the monopoly of the international
pharmaceutical giants on compounds they are copying." Id. Both the Pfizer and
GlaxoSmithKline cases arose because Chinese drug makers attempted to copy the drugs at
issue before the patents on them were granted by developing either different ways to
make the same-as the case with Viagra-or similar-as the case with Avandia-chemical
compounds. Id.; see also notes 47-50 and accompanying text.
102. From 2002 to 2003, the number of patent applications in China grew by more that
20 percent; the China State Intellectual Property Office received 105,318 applications for
inventions in 2003. ANNUAL REPORTS 2003, China State Intellectual Property Office,
http://www.sipo.gov.cn/sipo-English/ndbg/nb/ndbg2003/default.htm. For comparative
purposes, the U.S. Patent & Trademark Office received 342,441 applications for utility
patents in 2003, representing a growth of 2.4 percent over the number filed in 2002. See
U.S. PAT. & TRADEMARK OFF., U.S. PATENT STATISTICS, CALENDAR YEARS 1963 -
2003, http://www.uspto.gov/web/offices/ac/ido/oeip/taf/us-stat.pdf.
103. Jia, supra note 91.
104. See, e.g., More transnational Firms Invest in China, XINHUA NEWS AGENCY, Sept.
10, 1993, available at 1993 WL 12194406; China: Joint Venture Construction Plans for
$130,000,000 Pharmaceutical Manufacturing Project, SmithKline Beecham (SB) (USA),
China Natural Biological Products Corporation & Shanghai Institute of Biological
Products (China), ESP-REP. ON OIL GAS & PETROCHEMICALS DEV. WORLD, Dec. 1,
1992, available at 1992 WL 2732585.
105. See Einhorn et al., supra note 99.
106. See Stone Xu, An In-depth Look at Viagra's Abrupt Change of Fate in China,
CHINA IP (HURRYMEDIA), Sept. 28, 2004, available at
http://www.hurrymedia.com/jijia-new/news/2004-9-28-01.htm.
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In the cases of Viagra and Avandia, the local drug makers
chose to try to invalidate the patents that would threaten their
business. Considering the choices, the reexamination proceedings
are the best alternative for both Chinese business and foreign
investors. The decisions to invalidate the patents are not out-of-
step with international IPR standards, and the early successes
incentivize the Chinese companies to rely on the legal system as a
part of their business strategy.17 Such reliance is exactly the
attitude that is required for the success of IPR protection in China
and is consistent with the way IP-intensive industries conduct
business in the U.S. and the EU.
The challenge to Pfizer's Viagra patent in China is not
unique; the primary Viagra patent has faced several challenges and
has been invalidated not only in China, but also in the United
Kingdom'0 8 and the countries of the Andean Pact. 9 Only in Japan
has it successfully weathered a direct validity challenge. 0
Certainly, the patent laws in all of these countries are somewhat
different, but all meet the standards sef by the WTO."' However,
even if the patent laws were identical, the same facts may be
applied to the law differently, depending on the legal traditions of
each country. Nevertheless, the outcome of patent reviews in these
other countries in which the Viagra patent has been challenged not
only indicate that the invalidation decision of the China Patent
Reexamination Board is not unreasonable, but also can indicate
the likely outcome of Pfizer's appeal of that decision to the Beijing
First Intermediate People's Court.
107. See Scott Hensley, Pfizer's Use Patent For Viagra Suffers Setback in Britain,
WALL ST. J., Nov. 11, 2000, at B2.
108. Id.
109. Tanja Sturm, Andean Community Orders Ecuador to Suspend Pfizer Patent,
WMRC DAILY ANALYSIS, Nov. 18, 2002, available at 2002 WL 104062091; Tanja Sturm,
Andean Tribunal Lifts Sanctions Over Viagra Patent Dispute, WMRC DAILY ANALYSIS,
Sept. 16, 2002, available at 2002 WL 104031409; No Patent Protection for Viagra in Peru,
MARKETLETITER, Sept. 9, 2002, available at 2002 WL 7180904; see Viagra Patent Row,
CHEMISTRY & INDUS., Feb. 7, 2000, at 87; Colombia: Pfizer Loses Viagra Patent Rights, S.
AM. Bus. INFO., Jan. 27, 2000, available at 2000 WL 7712696.
110. Press Release, Pfizer Pharmaceuticals Ltd. (China) (July 10, 2003),
http://www.pfizer.com.cn/htmls/edexledex4-7.htm.
111. Understanding the WTO: The Organization, Members and Observers (Dec. 11,
2005), http://www.wto.org/english/thewto-e/whatis_e/tif-e/org6_e.htm.
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1. The Structure of the Viagra Patent.
The difficulties facing Viagra patents throughout the world
are primarily the result of the complicated history of the
development of the drug.' Pfizer originally developed and tested
Sildenafil citrate for the treatment of heart disease. During clinical
trials, Pfizer discovered the effectiveness of sildenafil citrate for
the treatment of male erectile dysfunction."' A patent covering the
compound sildenafil citrate would have provided the strongest
protection for Viagra.14 In the early 1990s, however, Chinese law
did not grant patents on pharmaceuticals or other chemical
compositions."5 Further complicating the acquisition of this patent
was the fact that the first novel use of sildenafil citrate was for
hypertension and other cardiological or circulatory disorders."6
Thus, Pfizer's patent had to be a "second use" patent-a type of
patent not recognized by all countries."7 By the time China's
patent law allowed patent protection for pharmaceutical
compounds, Viagra was no longer novel under Chinese patent law,
even if it had been at the time Pfizer first applied for its use
patent."8
Under China's current patent law, a "use" invention of a
pharmaceutical compound or composition can be protected by an
112. U.S. Viagra Ruling Stiffens Pfizer Claims, SHANGHAI DAILY, Nov. 8, 2002,
reprinted in Lehman, Lee & Xu, China E-ventions, http://www.chinalaw.cc/
newsletter/patent/20030110.htm.
113. Harris, supra note 63.
114. See discussion accompanying notes 119 through 133 infra; see also Wu, supra note
19, at 8.
115. American Embassy in China, Protecting Your Intellectual Property Rights (IPR)
in China, http://www.usembassy-china.org.cn/ipr/ovview.html (last visited November 28,
2005). See, Wu, supra note 19, at 8.
116. Lilly ICOS Ltd. v Pfizer Ltd. (No.]), [2001] F.S.R. 16, 234 - 35 (Ch D (Patents
Ct)).
117. The countries of the Andean Community do not recognize the patentability of
these so-called "second uses." According to Article 21 of Decision 486, Common
Intellectual Property Regime of the Andean Community, "products or processes already
patented and included in the state of the art.., shall not be subject to new patents on the
sole ground of having been put to a use different from that originally contemplated by the
initial patent." PASCALE BOULET, CHRISTOPHER GARRISON & ELLEN 'T HOEN, DRUG
PATENTS UNDER THE SPOTLIGHT: SHARING PRACTICAL KNOWLEDGE ABOUT
PHARMACEUTICAL PATENTS (2003), available at http://www.accessmed-
msf.org/documents/patents_2003.pdf. This decision has been interpreted by the Andean
Tribunal of Justice as disallowing so-called second-use pharmaceutical patents in the
countries of the Andean Community. Id.
118. Id.
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"invention" patent, a type of patent that is roughly equivalent to a
"utility patent" in the United States." 9 However, such a patent can
be written only in the form of a preparation process; the reasoning
is that when a new use as an active component of pharmaceuticals• • 120
is discovered, the substance itself does not become novel. Claims
must be drafted in the form: "Use of sildenafil citrate in the
preparation of pharmaceuticals against male erectile dysfunction,"
but not in the form "Use of sildenafil citrate for treatment of male
erectile dysfunction.' 12' The latter form is deemed a patent on a
treatment for disease, a type of patent protection not recognized
under the China Patent Law.'22 When drafted in the correct form,
the use patent claim can be applied to a first- or second-use of
pharmaceutical compound.12
In 1994, Pfizer applied for a Chinese patent for the use of
sildenafil citrate in the treatment of erectile dysfunction. At the
same time, it made similar applications in Japan, the European
Union, and other countries.124 Entitled "Pyrazolopyrimidinones for
119. See Sorell, supra note 20 at 326. Under U.S. patent law, "utility patents" are those
of a subject matter covered by 35 U.S.C. § 101. The categories of subject matter covered
under § 101 are: process (a series of steps for carrying out a given task), machine
(generally an apparatus containing moving parts), composition of matter (including
chemical compositions and mixtures of substances), and manufacture (any human-made
subject matter without moving parts). See 35 U.S.C. § 101 (2005). The vast majority (90
percent) of patents issued by the U.S. Patent & Trademark Office are utility patents. See
U.S. PAT. & TRADEMARK OFFICE, UNITED STATES PATENT STATISTICS, CALENDAR
YEARS 1963 - 2001, http://www.uspto.gov/web/offices/ac/ido/oeip/taf/usstat.pdf. Other
types of patents under U.S. law are: design (35 U.S.C. § 171; see Avia Group Int'l, Inc. v.
L.A. Gear Cal., Inc., 853 F.2d 1557 (Fed. Cir. 1998)) and plant (35 U.S.C. § 161, see Imazio
Nursery v. Dana Greenhouses, 69 F.3d 1560 (Fed. Cir. 1995)).
120. See Zhang Qing-kui, Patent Protection of Pharmaceutical Invention in China,
http://www.cnpatent.com/main/main5/yibao.htm (last accessed Nov. 8, 2005) (Zhang Qing-
kui was the Director General of the Chemical Examination Department of the Chinese
State Intellectual Property Office at the time this article was written).
121. Id. In contrast, the U.S. patent for Viagra directly claims the process of the
treatment: "A method of treating erectile dysfunction in a male animal, comprising
administering to a male animal in need of such treatment an effective amount of a
compound of formula (I). Claim 1, U.S. Patent No. 6,469,012 (filed May 13, 1994)
(issued Oct. 22, 2002).
122. China Patent Law, supra note 57, Art. 25 (2000).
123. See Zhang, supra note 120.
124. The EU patent EP0702555 entitled "Pyrazolopyrimidinones for the treatment of
impotence" listed a number of patents in countries both within and outside of the EU as
equivalent patents. Among these patents listed is the China patent publication number
1124926 entitled "Pyrazolopyrimidinones for the treatment of impotence." Because this
China patent is not available in translated form for comparison purposes, it is assumed
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the treatment of impotence," the patent application covered a
class of compounds that includes sildenafil citrate. 12' The patent
contained eleven claims; the relevant language of the only
independent claim was worded as follows:
1.The use of a compound of formula (I) [diagram of the basic
chemical structure and list of "R-groups"] or a pharmaceutically
acceptable salt thereof, or a pharmaceutical composition
containing either entity, for the manufacture of a medicament
for the curative or prophylactic treatment of erectile
dysfunction in a male animal, including man.12 6
This language complies with the requirements for a
pharmaceutical use patent under China Patent Law.1 27 The claim as
written referred to hundreds of compounds.2  Subsequent
dependent claims in the patent application referred to claims on
progressively smaller groups;129 the final claim in the patent
claimed the use of generic cGMP PDEv inhibitors."" The
specification first disclosed the use of a general class of
pyrazolopyrimidinones and equivalent salts, and then goes on to
identify a "preferred group of compounds" within claimed
Formula (I), a "more preferred group," and a "particularly
preferred group," each containing a smaller subset of the previous
that the scope of the EU patent and the China patent are the same. The U.S. patent of the
title Pyrazolopyrimidinones for the treatment of impotence," it should be noted, has a
broader claim scope than the EU patent of the same title but is not listed as an equivalent
on the EU patent. It should also be noted that the author has located one media source
that reported that the China patent had a scope narrower than the EU patent in that the
China patent listed only sildenafil citrate in the claim language rather than the entire class
of compounds termed pyrazolopyrimidinones. See Hongqing et al., supra note 59.
("Pfizer's U.K. patent included more than 100 chemicals .... In the Chinese case,
however, Viagra's patent listed only one chemical, siladenafil [sic] citrate .... ").
However, the claim scope suggested by this source seems unlikely for two reasons: first,
the EU patent lists the China patent as an equivalent, and second, the title of the China
patent clearly suggests the claim coverage of the class of pyrazolopyrimidinones, not only
sildenafil citrate.
125. European Patent Office No. EP 0 702 555 B1 (filed May 13, 1994).
126. Id. at 5:29-6:11.
127. See Zhang, supra note 120.
128. See European Patent Office No. EP 0 702 555 Bi (filed May 13, 1994).
129. A "dependent claim" is one that refers to (or depends upon) some other,
previously presented claim, while an independent claim stands alone without referring to
any other claim. Under U.S. patent law, these claiming principles are governed by 35
U.S.C. § 112 (2005).
130. Id. For a explanation of "cGMP PDEv inhibitor," see discussion infra note 134
and accompanying text.
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group of compounds.131 Reference is then made to "specially
preferred individual compounds of the invention" which "include"
nine named chemicals. 32 One of those named chemicals is
133sildenafil citrate.
The compound sildenafil citrate is part of a subclass of
134pyrazolopyrimidinones known as PDEv inhibitors. Briefly, the
PDEV inhibitor is a compound that inhibits the formation of a
category of PDE, or phosphodiesterase enzyme, that plaYs an
important role in the relaxation of smooth muscle fibers. The
selective inhibition of cGMP PDE (cyclic Guanosine
Monophosphate phosphodiesterase enzyme) leads to elevated
levels of cGMP which, in turn, provide the basis for relaxation of
116smooth muscles fibers. Smooth muscle fibers largely comprise
the structure of the heart, and relaxation of these fibers is effective
for the treatment of heart disease such as, inter alia, hypertension,
angina, and congestive heart failure. 37 The relaxation of smooth
muscle fibers in the penis is a critical step in the development of a
penile erection and cGMP PDE inhibitors can effectively treat
male erectile dysfunction.
18
2. Invalidity of Pfizer's Viagra Patent. The challenge to
Pfizer's Chinese patent emphasized the arguments used in Lilly v.
Pfizer to invalidate the equivalent patent in the U.K. and then in
the EU.3 9 In the U.K. case, Lilly ICOS LLC challenged the
131. Id.
132. Id.
133. Lilly, [2001] F.S.R. 16 at 215.
134. See id. at 207-14. (providing an excellent summary of the biochemistry and
pharmacology of cGMP PDE inhibitors as related to the Viagra patent).
135. Id. at 210-211.
136. Id. at 211.
137. Id. at 214.
138. Id.
139. See Case to Invalidate the Patent right of Viagra on Trial, SANYOU IP
NEWSLETTER (Beijing Sanyou Intellectual Property Agency, Beijing, P.R.C.) (Vol. 13,
No. 4) (2002) (reporting that during the reexamination hearings at SIPO, the party making
the request for the invalidation cited the following reasons: "1. the technical solution of
the patent possessed neither novelty nor inventiveness as compared with the references
they searched out; 2. the amendments to the claims went beyond the original disclosure of
the specification; 3. House of Lords in England declared on June 17, 2002 that the patent
right of Viagra filed by Pfizer Inc. to be invalid") (on file with author); Duan Hongqing et
al., supra note 59 (reporting that, according to Xu Guowen, the lead attorney for the
Chinese pharmaceutical companies seeking the reexamination, the complaint "cited the
same evidence that the British High Court used to strike down the Viagra patent").
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validity of Pfizer's U.K. patent on the basis of anticipation,
obviousness, insufficiency, and added matter.' 4° The anticipation
argument was advanced on the basis of a single document
published in April 1993;141 the obviousness argument was founded
on a number of documents, but three were relied upon most
heavily. 142 The U.K. court that invalidated Pfizer's patent for
obviousness, did not find that Pfizer's patent had been anticipated
by prior art, and found the insufficiency and added matter
arguments to be relevant only to the issue of claim construction. 14 3
The arguments presented to the U.K. court illustrate the evidence
and arguments presented to the China Patent Reexamination
Board by the parties seeking reexamination of the China Viagra
patent. Similar arguments will almost certainly be made at Pfizer's
appeal to the Beijing First Intermediate People's Court.
Considering the current state of China's patent law, it seems likely
that these arguments will be successful at the Intermediate Court
and again at the Supreme People's Court if another appeal is made
by Pfizer. 44 At the end of the long appeals process, it is likely that
the courts will invalidate Pfizer's patent for lack of inventiveness
under China Patent Law, Art. 22 3 (2000).
(a) Invalidity for Lack of Disclosure. The initial decision of
SIPO to invalidate the Viagra patent is difficult to assess because
140. Lilly, [2001] F.S.R. 16 at 206.
141. Id. at 225 (identifying the document S.G. Korenman & S.P. Viosca, Treatment of
Vasculogenic Sexual Dysfunction with Pentozifylline, 41 J. AM. GERIATRICS SOC. 363
(1993)).
142. These major documents were: J. Rajfer et al., Nitric Oxide as a Mediator of
Relaxation of the Corpus Cavernosum in Respect to Nonadrenergic, Noncholinergic
Neurotransmission, 362 N.E. J. MED. 90 (1992); K.J. Murray, Phosphodiesterase VA
Inhibitors, 6 DRUG NEWS & PERSPECTIVES 150 (1993); Margaret Ann Bush, THE ROLE
OF THE L-ARGININE-NITRIC OXIDE-CYCLIC GMP PATHWAY IN RELAXATION OF
CORPUS CAVERNOSUM SMOOTH MUSCLE, Ph.D. Dissertation, University of California,
Los Angeles (1993). Lilly, [2001] F.S.R. 16 at 206.
143. Id.
144. Chinese legal procedure allows courts on appeal to decide not only questions of
law, as in U.S. appellate courts, but also questions of fact. Mo Zhang and Paul J. Zwier,
Burden of Proof. Developments in Modern Chinese Evidence Rules, 10 TULSA J. COMP. &
INT'L L. 419, 459 (2003). While in a parallel U.S. court action, the appellate court would
send the case back to the U.S. Patent Office for a ruling in accord with its decision because
it could not consider new arguments, appellate courts in China can consider both issues of
law and of fact, as well as issues not raised in the original proceedings. Therefore, the
Intermediate People's Court will likely consider the arguments of novelty and obviousness
that were not ruled upon by the China SIPO but were raised by the parties seeking
reexamination of the Pfizer patent.
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an official opinion has not yet been released. However,
considering the EU patent construction in conjunction with the
comments of the U.K. court in Lilly v. Pfizer and the media
reports from China following the SIPO decision, the SIPO
Reexamination Board's invalidation does not appear
unreasonable. The patent application did not disclose sildenafil
citrate as the compound that was the active ingredient effective in
treating erectile dysfunction; rather, the patent identified nine
compounds, of which sildenafil citrate was one, as the "most
preferred" for the practice of the invention. Such disclosure may
run afoul of several requirements of China Patent Law.
Principally, the applicant is required to disclose enough
information to enable a "person skilled in the relevant field of
technology" to understand and exploit the invention accordingly.
This requirement is expanded upon by the Implementing
Regulations which require that the .description of the invention
"[describe] in detail the optimally selected mode contemplated by
the applicant for carrying out the invention or utility model. . .,,Y
Media and industry reports out of China that claim the Patent
Reexamination Board's decision to invalidate the patent was
based on insufficient disclosure and an inability of the examiners
to reproduce the invention suggest that Pfizer's application may
not have met these requirements as established by China Patent
Law, Art. 26 3 (2000) and Implementing Regulations of the
China Patent Law, Rule 18(5) (2001).
Under U.S. patent law, a similar requirement for disclosure in
the patent application is that of "best mode."' 46 The applicant for a
U.S. patent must disclose in the specification, but not in the claims
themselves, the "best mode" for the practice of the invention as
defined by the subjective preference of the inventor at the time the
145. Renmin Gongheguo Zhuanlifa Shishi Xize [Implementing Regulations of the
Patent Law of the People's Republic of China (2001)], [hereinafter Implementing
Regulations of the China Patent Law (2001)] Rule 18(8), http://www.sipo.gov.cn/
sipo-English/flfg/zlflfg/t2002O327_33871.htm.
146. 35 U.S.C. § 112 requires that the specification include the following: (i) a written
description of the invention; (ii) the manner and process of making and using the
invention; and (iii) the best mode contemplated by the inventor of carrying out the
invention. 35 U.S.C. § 112 (2004); see also Mark S. Cohen, Compliance with the Written
description requirement in Biotechnology and Pharmaceutical Patents, 805 PLI/PAT 9
(2004).
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patent application was filed. 147 From the construction of the China
Viagra patent, it would seem that the U.S. best mode requirement
would be met, as sildenafil citrate was one of the compounds listed
in the specification of the "most preferred. 148 However, the U.S.
best mode requirement is not -as strict as the comparable China
patent requirement, as U.S. law does not require a detailed
description of the optimally selected model, i.e. the best mode. 49
(b) Invalidity for Lack of Novelty. Even if the People's Court
were to find that the Patent Reexamination Board erred in the
application of the disclosure requirements, Pfizer's patent could be
invalidated because it was either not novel or was obvious.5
Under the China Patent Law, there are three requirements for
patentability: novelty, inventiveness, and practical applicability. 5'
According to reports from the Chinese legal community, Pfizer's
patent specification created a dilemma: arguments for the patent's
creativity undermined Pfizer's assertion that the specification met
the demands for openness. Conversely, Pfizer's assertion that the
demands for openness were met undermined evidence of the
claim's creativity.' Not coincidentally, in the U.K. case Lilly v.
Pfizer, Lilly also claimed that the Pfizer patent failed to establish
novelty and non-obviousness.'53 "Inventiveness" under China
147. 35 U.S.C. § 112 ("The specification shall contain a written description of the
invention ... and shall set forth the best mode contemplated by the inventor of carrying
out his invention.").
148. There is no requirement in the U.S. patent system that the application "flag," or
otherwise draw attention to, the best mode, only that the best mode be included in the
specification. In practice, the applicant for a U.S. patent will typically "bury" the best
mode in the text of the specification so as not to draw attention to the preferences of the
inventor.
149. 37 C.F.R. § 1.71(b), in expanding upon 35 U.S.C. § 112, provides that "The
specification must set forth the precise invention for which a patent is solicited, in such
manner as to distinguish it from other inventions and from what is old. It must describe
completely a specific embodiment of the process, machine, manufacture, composition of
matter or improvement invented, and must explain the mode of operation of principle
whenever applicable." 37 C.F.R. § 1.71(b) (2004). This requirement is notably different
from, and requires less specificity than, the disclosure required in Implementing
Regulations of the China Patent Law, Rule 18(5) (2001) which requires a detailed
description of the optimally selected mode.
150. Recall that the review by the People's Court is de novo and therefore need not be
limited to the issues addressed by the Patent Reexamination Board. Zhang and Zwier,
supra note 144 at 459.
151. China Patent Law, supra note 57, Art. 22.
152. See Xu, supra note 65.
153. Lilly, [2001] F.S.R. 16 at 206.
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Patent Law is analogous, but not identical, to the concept of
"obviousness" under the U.S.1 s4 and U.K.155 patent systems.
The U.K. court opinion in Lilly v. Pfizer lists a single
publication that Lilly claimed anticipated Pfizer's patent, thereby
destroying novelty under the U.K. definition.56 In China, a valid
patent must possess novelty, where "[n]ovelty means that, before
the date of filing, no identical invention or utility model has been
publicly disclosed in publications in the country -or abroad or has
been publicly used or made known to the public by any means in
the country. .... "'57 If this listed publication did, in fact, disclose the
invention claimed in the Pfizer patent, a court or other reviewing
body must determine whether the Pfizer invention in the China
patent application is novel as required under China Patent Law,
Article 22 paragraph 2 (2000). However, based on the discussion
of this publication in Lilly v. Pfizer, it is unlikely that a Chinese
court would hold that this publication anticipates Pfizer's claimed
invention. Indeed, it may be the weakness of this anticipation
argument based on the Korenman publication that resulted in the
154. Sorell, supra note 20, at 326.
155. JOHN GLADSTONE MILLS, DONALD C. REILEY & ROBERT HIGHLEY, PATENT
LAW BASICS § 20:2.3 (2004) [hereinafter MILLS, PATENT LAW BASICS]. The United
Kingdom Patent Act § 3(3) defines the "inventive step" required for patentability: "An
invention shall not be taken to involve an inventive step if it is obvious to a person skilled
in the art, having regard to any matter which forms part of the state of the art by virtue of
section 2(2) ... " "In cases attempting to invalidate patents as being obvious, courts in the
United Kingdom rely on qualified expert witnesses to testify on whether a patent claim
would have been 'obvious to a person skilled in the art' at the time the invention was first
made." MILLS, PATENT LAW BASICS at § 20:2.3. The U.K. standard for determining
obviousness is similar to that used in the United States following Graham v. John Deere
Co., 383 U.S. 1, 14, 17 (1966). MILLS, PATENT LAW BASICS at § 20:2.3. The U.K.
obviousness test is:
(1) First the court identifies the inventive concept;
(2) Next, the court will assume the mantle of the normally skilled but
unimaginative addressee in the art at the relevant date and will impute to him
what was at that date, common general knowledge in the art in question;
(3) The court should then identify what, if any, differences exist between the
matters cited as being "known or used" and the alleged invention;
(4) Finally, the court has to decide whether viewed without knowledge of the
alleged invention, those differences constitute steps which would have been
obvious to the skilled man or whether they required any degree of invention.
Id. (citing Windsurfing International Inc. v. Tabur Marine (Great Britain) Ltd., (1985)
R.P.C. 59, 73).
156. Lilly, [2001] F.S.R. 16 at 225. Note, however, that the opinion stated in dicta that
Lilly's argument for anticipation failed. Id. at 260.
157. China Patent Law, supra note 57, Art. 22.
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China SIPO invalidating Pfizer's patent on the basis of prior
disclosure rather than novelty.
The anticipation argument in Lilly v. Pfizer failed on several
levels, all of which would be relevant to a consideration of novelty
under China Patent Law, Article 22 paragraph 2 (2000). First,
Korenman's stated objective was to evaluate the use of the
chemical pentoxifylline to treat erectile dysfunction in men.1 8 Lilly
claimed that pentoxifylline is a cGMP PDE inhibitor and that the
publication describes the oral administration of such an inhibitor
for the treatment of erectile dysfunction.159 The U.K. court rejected
this argument on the basis of expert testimony.16° The court noted
that pentoxifylline was not a PDE inhibitor. Even if it were a PDE
inhibitor, it is not a selective cGMP PDE inhibitor as are the
compounds claimed in Pfizer's patent."' Further, the court noted
that while Lilly itself performed extensive tests aimed at proving
pentoxifylline is an effective cure for erectile dysfunction, the
Korenman publication did not prove this point.6 6 For these
reasons, the court held that the Korenman publication could not
have anticipated Pfizer's invention.
It should be noted that this decision in the U.K. was published
in November 2000, before the China Viagra patent was issued or
petitioned for reexamination. The Chinese pharmaceutical
companies seeking the invalidation of the Viagra patent were
undoubtedly aware of the U.K. court analysis of the novelty
argument, yet they appear to have pleaded it despite its rejection
under U.K. patent law. While a source that explains this strategy
cannot be located, it seems likely that the Chinese pharmaceutical
companies simply made the same arguments Lilly made to the
U.K. courts in the hope that the China Patent Reexamination
Board would view the Korenman publication differently.
(c) Invalid because obvious. Unlike the novelty challenge
raised by Lilly in the U.K., the obviousness challenge is supported
by a strong argument that convinced the U.K. Patents Court to
invalidate Pfizer's U.K. patent and which would likely do the same
158. Lilly, [2001] F.S.R. 16 at 258.
159. Id.
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under China's patent law. In the opinion dismissing Pfizer's appeal
of the Patents Court's decision in Lilly v. Pfizer, Lord Justice
Aldous of the Supreme Judicature Court of Appeal summarized
the court's position on obviousness in the Pfizer patent:
[A]s of the date of the Viagra patent, the product Viagra was
known. It was also known that it was a selective cGMP PDEV
inhibitor. It was also known that cGMP PDEV removed cGMP
which caused or contributed towards an erection. It had also
been suggested that such inhibitors could be useful in the
treatment of impotence. Against that background this Court
had to consider whether it was inventive to appreciate that
Viagra, when taken orally, would cause or contribute to an
erection. This Court concluded that it was not. The publication
of the work done at the University of California was a crucial
step in the Court's reasoning.' 64
China Patent Law requires an "inventive step" for a valid
patent, where "an invention is considered to involve an inventive
step if, having regard to the state of the art, it is not obvious to a
person skilled in the art or the so-called 'notional skilled
technician.' ' 16' The requirement of invention is established in
China Patent Law, Article 22 paragraph 3 (2000) and is typically
explained in Chinese textbooks in the light of the European Patent
Convention standards of non-obviousness.166 The inventive step
requires an "obvious difference in substantive or essential features
compared to the prior art ('existing technology'), or that an
ordinary or 'notional' technician skilled in the field of the
invention cannot directly obtain from existing technology all
necessary technical features which constitute the invention.,
16
Pfizer's response to this requirement can be seen in the language
used in its patent application.6 Nevertheless, the U.K. courts were
not persuaded by Pfizer's claims of inventiveness and for similar
164. Lilly IOCS Ltd. v. Pfizer Ltd., [2002] EWCA Civ 1, (CA (Civ Div)), available at
2002 WL 45115.
165. FENG, supra note 68, at 216 (citing Art. 56, EPC 1973).
166. Id. (noting the non-obviousness standard of the European Patent Convention).
167. Id.
168. For example, the specification of the Pfizer patent includes the language:
"Unexpectedly, it has been found that these disclosed compounds are useful in the
treatment of erectile dysfunction. Furthermore, the compounds may be administered
orally, thereby obviating the disadvantages associated with i.c. administration." U.S.
Patent No. 6,469,012 B1 (filed May 13, 1994) (issued Oct. 22, 2002), 1:59 - 66.
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reasoning, and there is no reason to suppose that the Chinese
courts would be so persuaded.
Where two or more published documents are referenced to
establish the obviousness, or lack of inventiveness, of a claimed
invention, reported Patent Reexamination Board cases suggest
that there are several important factors for consideration:
(1)how far apart the technological fields of the two or more
reference documents are;
(2)whether the technical problem resolved by the indispensable
technical features of the invention is the same as that resolved
by the corresponding prior art in the reference documents;
(3)whether the invention arrived at by combining the relevant
prior art in the reference documents is an idea that the notional
skilled technician can arrive at through routine analysis, or an
idea that can only be arrived at by unconventional thinking and
overcoming long-standing technical prejudice; and
(4)whether the result produced by such a combination can be
expected by the notional skilled technician in the art.
169
Certainly these factors are not binding on the Beijing First
Intermediate People's Court, but 70 -they undoubtedly provide
indirect reference for the court. The opinion of the U.K. court in
Lilly v. Pfizer makes clear that Pfizer's patent has little chance of
surviving an appeal for lack of inventiveness. Of the three primary
publications considered by the U.K. court, all are in the same
technical field as the patent. 7' Indeed, two of the publications
present research conducted by the research group of Nobel
Laureate Professor Louis Ignarro at UCLA: Professor Ignarro
served as the principle expert witness for Pfizer in both Lilly v.
Pfizer in the U.K. and in the China Patent Reexamination Board
hearings. The publications further consider indispensable
technical features of the Pfizer patent, especially in regards to the
use of cGMP PDE inhibitors in the treatment of erectile
169. FENG, supra note 68, at 218 - 19.
170. The Chinese legal system is a "civil law" system based on written statutes and, as
such, court decisions do not constitute binding precedent but serve merely as guidance to
courts. Jerome A. Cohen & John E. Lange, The Chinese Legal System: A Primer for
Investors, 17 N.Y.L. SCH. J. INT'L & COMP. L. 345, 350 (1997).
171. Lilly, [2001] F.S.R. 16 at 258.
172. See id. at 226; Duan Hongqing et al., supra note 59.
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dysfunction.173 The U.K. courts concluded at the Patent's Court
and the Appellate Court levels, as well as at the House of Lords,
that the Pfizer patent was obvious. This conclusion can be
analogized to the Chinese non-obviousness standard: an invention
cannot receive a patent when the "invention [is] arrived at by
combining the relevant prior art in the [publications was] [and is]
an idea that the notional skilled technician can arrive at through
routine analysis... and the result produced by such a combination
can be expected by the notional skilled technician in the art.',
17 4
The U.K. patent system is well-established and is beyond
criticism related to adherence to TRIPS standards. The U.K.
courts invalidated the same patent that was invalidated by the
Patent Reexamination Board in China, yet unlike China, the U.K.
did not sustain any meaningful criticism for the decision. Clearly,
the invalidation in China was for failure to meet China's disclosure
requirements, an issue that was not relevant to the arguments in
Lilly v. Pfizer. Nevertheless, it appears clear that, even without a
body of Chinese case law with which to interpret the issue, Pfizer's
Chinese patent could and should be invalidated for failure to meet
the inventiveness requirement under China Patent Law, Art. 22
3 (2000). Even if the Beijing First Intermediate People's Court
reverses the Patent Reexamination Board invalidation under
China Patent Law, Art. 26 2 (2000), Pfizer is fighting a losing
battle for its Viagra patent in China.
IV. CONCLUSION
It is clear that intellectual property rights in China are not
afforded the same degree of protection as are IPRs in the United
States, the EU, or even Japan. There is a great deal of criticism
levied against China in this regard, especially from the United
States. However, it is imperative that the world view the treatment
of IPRs in China in the appropriate context. China, the oldest
continuous civilization in the history of the world, has a cultural
history reaching back several thousand years that does not include
the concept of intellectual property. Not only were IPRs
unnecessary in traditional Chinese culture because of the lack of a
healthy merchant class and trade with foreigners, but IPRs
173. See Lilly, [2001] F.S.R. 16 at 226 - 27.
174. FENG, supra note 68, at 216.
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conflicted with the Chinese concept of a harmonious society. From
these roots, China has made dramatic progress in the
implementation of laws to protect intellectual property.
However, to change a cultural collective mindset is
necessarily a slow process and can only be accomplished where the
changes result in a recognizable benefit. Through the 1990s, the
U.S. was quick to force IPR laws on China, using the threat of
trade isolation to push for the adoption of laws following the U.S.
model. China adopted many of these laws to move into compliance
with TRIPS and to gain entry into the WTO, and to avoid trade
wars with the U.S. But economic domestic development in China
lagged behind the growing international trade and foreign
investment, and the IPR laws in China were used primarily to
protect, or to attempt to protect, the IPRs of foreign businesses."'
However, as domestic development in China grows, so do the
potential benefits Chinese businesses can realize from the
enforcement of IPR laws.
The current case of the invalidation of Pfizer's Viagra patent
in China presents an early example of how Chinese business-in
this case the domestic pharmaceutical industry-is adopting IPR
laws as a business strategy. Here, domestic drug companies had
begun to produce generic forms of Pfizer's erectile dysfunction
drug Viagra before Pfizer was granted a patent on Viagra in
China. Upon the grant of a patent to Pfizer, the domestic drug
companies chose to not simply infringe Pfizer's patent rights, but
rather decided to petition the government to invalidate the patent.
Pfizer's patent was invalidated by the government's Patent
Reexamination Board in a decision that attracted a great deal of
criticism from the U.S. government and pharmaceutical industry.
However, a similar Viagra patent in the U.K. had also been
invalidated by the U.K. courts, and from that court's reasoning, it
does not appear that China's decision was out-of-step with
international IPR standards. Rather than criticize China's legal
challenge of Pfizer's patent-as well as of other pharmaceutical
patents-the international community should recognize this event
as the beginning of a new phase in the promise of intellectual
property rights protection in the People's Republic of China.
175. U.S. Dept. of State, China: 2005 Investment Climate,
http://www.state.gov/e/eb/ifd/2005/42000.htm (last visited Nov. 29, 2005).
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